Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part I

Journal of Psychiatric Practice

Volumn 12, Issue 4, 2006, Pages 244-249

  Preskorn, Sheldon H ^a,b   Borges, Silvana ^c   Flockhart, David ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ACAMPROSATE; AGALSIDASE BETA; ALEFACEPT; ALFUZOSIN; AMANTADINE; AMLODIPINE PLUS ATORVASTATIN; AMPRENAVIR PHOSPHATE; APOMORPHINE; APREPITANT; ATAZANAVIR; AZACITIDINE; BORTEZOMIB; CARBONATE DEHYDRATASE INHIBITOR; CETUXIMAB; CINACALCET; CLOFARABINE; DESIPRAMINE; DEXTROMETHORPHAN; DIAZEPAM; DIURETIC AGENT; DONEPEZIL; DULOXETINE; ENFUVIRTIDE; ENTECAVIR; ERLOTINIB; ESTRADIOL; ESZOPICLONE; EXENDIN 4; FINACEA; GALANTAMINE; GEFITINIB; HORMONE RECEPTOR STIMULATING AGENT; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; IBANDRONIC ACID; IMIPRAMINE; INFLUENZA VACCINE; KETAMINE; LANTHANUM CARBONATE; LARONIDASE; MEMANTINE; NALTREXONE; OXYBUTYNIN; PALONOSETRON; PEGAPTANIB; PEGVISOMANT; PEMETREXED; PHENCYCLIDINE; RAMELTEON; RIFAXIMIN; RIVASTIGMINE; ROFECOXIB; ROSUVASTATIN; SOLIFENACIN; TACRINE; TADALAFIL; TELITHROMYCIN; TINIDAZOLE; TIOTROPIUM BROMIDE; TIPRANAVIR; TOSITUMOMAB I 131; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; ZEMAIRA;

ALCOHOLISM; ALZHEIMER DISEASE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFECT; DRUG ELIMINATION; DRUG INDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; INSOMNIA; MAJOR DEPRESSION; NONHUMAN; PARKINSON DISEASE; PSYCHOPHARMACOTHERAPY; REVIEW;

ALCOHOL DETERRENTS; ALCOHOLISM; ALZHEIMER DISEASE; BRAIN; DOPAMINE AGENTS; HUMANS; MEMANTINE; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; TAURINE;

EID: 33746803829     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200607000-00006     Document Type: Review

References (33)

1. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part I). J Psychiatr Pract 2003;9:376-84.
2. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II). J Psychiatr Pract 2004;10:177-81.
3. Preskorn SH, Flockhart D. 2006 guide to psychiatric drug interactions. Primary Psychiatry 2006;13:35-64.
4. Campral package insert. In: Physicians' desk reference. Montvale, NJ: Thomson PDR; 2006:1175-7 (www.frx.com/pi/campral_pi.pdf, accessed July 1, 2006).
5. Zornoza T, Cano MJ, Polache A, et al. Pharmacology of acamprosate: An overview. CNS Drug Rev 2003;9:359-74.
6. Harris BR, Prendergast MA, Gibson DA, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002;26:1779-93.
7. De Witte P, Littleton J, Parot P, et al. Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs 2005;19:517-37.
8. Koob GF, Mason BJ, De Witte P, et al. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res 2002;26:586-92.
9. De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict Behav 2004;29:1325-39.
10. Nagy J, Horvath C, Farkas S, et al. NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurons. Neurochem Int 2004;44:17-23.
11. al Qatari M, Khan S, Harris B, et al. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res 2001;25:1276-83.
12. Berton F, Francesconi WG, Madamba SG, et al. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998;22:183-91.
13. Saivin S, Hulot T, Chabac S, et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998;35:331-45.
14. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596-606.
15. Namenda package insert. In: Physicians' desk reference. Montvale, NJ: Thomson PDR; 2006: 1199-1202. (www.frx.com/pi /namenda_pi.pdf, accessed July 1, 2006).
16. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
17. Parsons CG, Danysz W, Zieglgansberger W. Excitatory amino acid neurotransmission. Handb Exp Pharmacol 2005;169:249-303.
18. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat Rev Drug Discov 2006;5:160-70.
19. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: Low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005;2:155-65.
20. Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: Uncompetitive antagonism. J Physiol 1997;499(Pt 1):27-46.
21. Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43:91-104.
22. Periclou A, Ventura D, Rao N, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006;79:134-43.
23. Micuda S, Mundlova L, Anzenbacherova E, et al. Inhibitory effects of memantine on human cytochrome P450 activities: Prediction of in vivo drug interactions. Eur J Clin Pharmacol 2004;60:583-9.
24. Rao N, Chou T, Ventura D, et al. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: A single-center, multiple-dose, open-label study. Clin Ther 2005;27:1596-606.
25. Yao C, Raoufinia A, Gold M, et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol 2005;45:519-28.
26. Periclou AP, Ventura D, Sherman T, et al. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004;38:1389-94.
27. Enz A, Gentsch C. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology 2004;47:408-13.
28. Wenk GL, Quack G, Moebius HJ, et al. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 2000;66:1079-83.
29. Preskorn SH, Baker B. The overlap of DSM-IV syndromes: Potential implications for the practice of polypsychopharmacology, psychiatric drug development, and the human genome project. J Psych Pract 2002;8:170-7.
30. Preskorn SH. Modern drug development and the human genome project. Series of columns published in the Journal of Psychiatric Practice (can be accessed at www.preskorn.com/column4.html).
31. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs Healthcare System: Part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005;11:5-15.
32. Silkey B, Preskorn SH, Golbeck A, et al. Complexity of medication use in the Veterans Affairs Healthcare System: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract 2005;11:16-26.
33. Preskorn SH. Multiple medication use in patients seen in the Veterans Affairs Healthcare System: So what? J Psychiatr Pract 2005;11:46-50.